Related Experiment Video

Updated: Feb 25, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.6K

Regorafenib as treatment for patients with advanced hepatocellular cancer

Kiruthikah Thillai1, Krishnie Srikandarajah1, Paul Ross1

  • 1Department of Medical Oncology, Guy's & St Thomas' NHS Trust, Great Maze Pond, London Bridge, London SE1 9RT, UK.

Future Oncology (London, England)
|August 3, 2017
PubMed

Insights

Regorafenib improves survival for advanced liver cancer patients who progressed on sorafenib. This review covers regorafenib

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality.
  • Sorafenib has been the standard first-line treatment for advanced HCC for years.
  • Limited treatment options exist for patients progressing on sorafenib.

Purpose of the Study:

  • To review the pharmacokinetic and pharmacodynamic properties of regorafenib.
  • To evaluate the efficacy and tolerability of regorafenib in advanced HCC.
  • To provide insights into second-line treatment strategies for HCC.

Main Methods:

  • Literature review of clinical trials and studies on regorafenib.
  • Analysis of pharmacokinetic and pharmacodynamic data.
  • Assessment of survival, efficacy, and safety data from relevant studies.

Main Results:

  • Regorafenib demonstrated significant improvement in survival for patients with advanced HCC who progressed on sorafenib.
  • The drug's pharmacokinetic and pharmacodynamic profile supports its efficacy.
  • Tolerability data indicate manageable side effects in the studied population.

Conclusions:

  • Regorafenib is an effective second-line treatment option for advanced HCC.
  • Understanding regorafenib's properties aids in optimizing patient outcomes.
  • Further research may explore combination therapies or novel treatment approaches.
Keywords:
VEGFangiogenesishepatocellular carcinomaregorafenib

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

10.0K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508